Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Says recently completed in vitro studies for new messenger ribonucleic acid therapeutic show ‘statistically significant reduction’ in proliferation and migration of breast and liver cancer. Study was part of Roquefort’s new anti-cancer mRNA therapeutics platform focused on the Midkine growth target. The MDK mRNA programme was tested in validated in vitro cancer models to evaluate effect on growth and migration. Roquefort acknowledges that these are early results but says therapeutic shows potential to become first-in-class cancer treatment if they are replicated in clinical trials. It recently updated its filed patents to protect MDK mRNA programme compositions and methods. Programme now will move to in vivo studies.

Chief Executive Officer Ajan Reginald says: ‘mRNA is the most attractive field in Biotech and, within this highly innovative field, we are developing a unique Midkine niche...These experiments were completed on time and within budget and form a critical part of our Midkine portfolio and our broader anti-cancer portfolio of five programmes.’

Current stock price: 6.74 pence, up 5.7% in London on Tuesday

12-month change: down 16%

Copyright 2023 Alliance News Ltd. All Rights Reserved.